Castle Biosciences News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

01.09.22	Castle Biosciences to Participate in Upcoming Investor Conferences (Businesswire)
24.08.22	Castle Biosciences to Host Investor Day on Sept. 20, 2022 (Businesswire)
04.08.22	American Gastroenterological Association (AGA) Clinical Practice Update States That TissueCypher® May Be Beneficial for Risk-Stratification of Patients with Non-Dysplastic Barrett’s Esophagus (Businesswire)
03.08.22	Castle Biosciences to Present at the Canaccord Genuity 42nd Annual Growth Conference (Businesswire)
25.07.22	Castle Biosciences to Release Second Quarter 2022 Financial Results and Host Conference Call on Monday, August 8 (Businesswire)
25.07.22	DecisionDx®-Melanoma Ordered More Than 100,000 Times for Patients Diagnosed with Cutaneous Melanoma (Businesswire)
20.07.22	Presentation at 2022 AAD Innovation Academy to Showcase the Risk Stratification of DecisionDx®-Melanoma and its Role in the Management of Patients with Cutaneous Melanoma (Businesswire)
18.07.22	Castle Biosciences Honored with a 2022 Arizona Top Workplace Award (Businesswire)
23.06.22	Patients with Uveal Melanoma Tested with DecisionDx®-UM Report Gaining Value from Test Results In Study Conducted In Collaboration with the Melanoma Research Foundation’s CURE OM Initiative (Businesswire)
22.06.22	Castle Adds to Evidence Supporting Its Skin Cancer Test Portfolio through Multiple Data Presentations at the SDPA Annual Summer Dermatology Conference 2022 (Businesswire)
20.06.22	Castle Biosciences Announces Support for OHSU’s War on Melanoma™ (Businesswire)
14.06.22	Collaborative Study with Melanoma Research Foundation Confirms Patients Diagnosed with Melanoma Desire Testing with DecisionDx®-Melanoma (Businesswire)
08.06.22	Castle Biosciences to Present at the JMP Securities Life Sciences Conference (Businesswire)
01.06.22	The Castle Story... (RTTNews)
27.05.22	Castle Biosciences’ DecisionDx®-Melanoma Test Receives 2022 MedTech Breakthrough Award (Businesswire)
25.05.22	Data Demonstrating DecisionDx®-Melanoma’s Ability to Risk-Stratify Patients According to Melanoma-Specific Survival to be Shared during the 2022 ASCO Annual Meeting (Businesswire)
24.05.22	TissueCypher® Outperforms Pathologist Diagnoses When Predicting Progression in Patients Diagnosed with Barrett’s Esophagus with Low-Grade Dysplasia (Businesswire)
20.05.22	Grant From Research to Prevent Blindness and Castle Biosciences Supports Medical Student Research in Ocular Cancer (Businesswire)
19.05.22	Data from Second Independent Multi-Center Study of Patients with High-Risk Cutaneous Squamous Cell Carcinoma Confirms Independent Risk-Stratification Performance of DecisionDx®-SCC (Businesswire)
10.05.22	Castle Biosciences Collaborates with The Sun Bus to Provide Free Skin Cancer Screenings (Businesswire)
10.05.22	ADCT Awaits Cami Trial Data, CSTL Boosts Revenue Outlook, ANNX To Report HD Trial Data In Q2 (RTTNews)
09.05.22	Castle Biosciences Reports First Quarter 2022 Results (Businesswire)
06.05.22	Camille Schrier, Miss America 2020, and Castle Biosciences Partner to Expand Awareness of Genetic Testing in Depression and Anxiety (Businesswire)
03.05.22	Castle Biosciences Recognizes Skin Cancer Awareness Month through Its Support of Patient-Focused Initiatives (Businesswire)
29.04.22	Castle Biosciences Announces Expanded U.S. Federal Supply Schedule Contract Covering Its Entire Dermatologic Cancer Portfolio of Tests (Businesswire)
26.04.22	Castle Biosciences Completes Acquisition of AltheaDx (Businesswire)
25.04.22	Castle Biosciences to Release First Quarter 2022 Financial Results and Host Conference Call on Monday, May 9 (Businesswire)
21.04.22	Expanded SEER Registries Dataset Shows Improved Survival for DecisionDx®-Melanoma Tested Patients Compared to Untested Patients (Businesswire)
20.04.22	Castle Biosciences to Present Data at the 18th European Association of Dermato Oncology (EADO) Congress (Businesswire)
18.04.22	Castle Biosciences Presents Data on Its Inflammatory Skin Disease Pipeline Test at the 4th Annual Revolutionizing Atopic Dermatitis (RAD) Conference (Businesswire)
05.04.22	Castle Biosciences to Present at the 21st Annual Needham Virtual Healthcare Conference (Businesswire)
29.03.22	Castle Biosciences Receives Advanced Diagnostic Laboratory Test (ADLT) Status for TissueCypher® Barrett’s Esophagus Test from the Centers for Medicare & Medicaid Services (CMS) (Businesswire)
25.03.22	Data to be Presented at the 2022 American Academy of Dermatology (AAD) Annual Meeting Demonstrate Ability of DecisionDx®-Melanoma and DecisionDx®-SCC to Inform Clinical Decision Making (Businesswire)
11.03.22	Independent Data Presented at Society for Surgical Oncology Conference Demonstrated DecisionDx®-Melanoma Outperforms T-Stage at Identifying Patients with Low Risk of Sentinel Lymph Node Positivity (Businesswire)
01.03.22	Castle Biosciences to Present at Upcoming Investor Conferences (Businesswire)
28.02.22	Castle Biosciences Reports Fourth Quarter and Full-Year 2021 Results (Businesswire)
14.02.22	Castle Biosciences to Release Fourth Quarter and Full-Year 2021 Financial Results and Host Conference Call on Monday, Feb. 28, 2022 (Businesswire)
07.02.22	Castle Biosciences to Present at the 11th Annual SVB Leerink Global Healthcare Conference (Businesswire)
03.02.22	Castle Biosciences Collaborates with the National Cancer Institute to Link DecisionDx®-Melanoma Testing Data with SEER Registries’ Cutaneous Melanoma Cases (Businesswire)
02.02.22	Castle Biosciences Named a Winner of the 2022 Top Workplaces USA Award (Businesswire)
24.01.22	Castle Biosciences to Present Data at Maui Derm for Dermatologists 2022 (Businesswire)
13.01.22	Recently Published Data Confirm DecisionDx®-SCC as a Significant and Independent Risk-Stratification Tool in Patients with Squamous Cell Carcinoma and One or More Risk Factors (Businesswire)
12.01.22	Data Published in Ocular Oncology and Pathology Demonstrates Highly Accurate Performance of DecisionDx®-UMSeq for Patients with Uveal Melanoma (Businesswire)
10.01.22	Castle Biosciences Announces Preliminary Fourth Quarter and Full-Year 2021 Results (Businesswire)
28.12.21	Castle Biosciences to Present at the 24th Annual Needham Growth Conference (Businesswire)
06.12.21	Castle Biosciences Completes Acquisition of Cernostics (Businesswire)
24.11.21	Castle Biosciences Presents Data Reinforcing the Clinical Utility of Its DecisionDx® Dermatologic Portfolio (Businesswire)
25.10.21	Pittsburgh Life Sciences Greenhouse Proudly Announces Portfolio Company Cernostics is Being Acquired by Castle Biosciences (PR Newswire)
21.06.21	Castle Biosciences is Listed in the Houston Chronicle’s "CHRON 100” as One of the 100 Most Successful Publicly Traded Companies in Houston (Businesswire)
09.06.21	Castle Biosciences Announces Receipt of New York Laboratory Permit (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Zurich Insur Gr	547.60	3.13 %	K V
Logitech Intl	70.26	2.57 %	K V
Givaudan	3’919.00	1.45 %	K V
ABB	49.58	1.08 %	K V
Swiss Re	127.20	0.99 %	K V
Holcim	89.86	-0.24 %	K V
Sika	229.00	-0.35 %	K V
Swisscom	505.50	-0.49 %	K V
Nestle	75.96	-0.73 %	K V
CieFinRichemont	117.65	-0.80 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Castle Biosciences Inc Registered Shs

Aktien Top/Flop

Meistgelesene Nachrichten